Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Pluri Inc PLUR

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and... see more

Bullboard (NDAQ:PLUR)

Post by lucaM1on Jul 27, 2022 8:56am

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.”

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries o As of July ...more  
Post by lucaM1on Jul 19, 2022 9:51am

Pluristem trial shows accelerated muscle regeneration

Phase III study of allogeneic PLX-PAD cells confirms “regenerative medicine is effective in elderly”.
Post by lucaM1on Jul 17, 2022 9:52am

HC Wainwright Reiterates On Pluristem After Encouraging Init

Yesterday Pluristem Therapeutics Inc (NASDAQ: PSTI) announced top-line results from its Phase 3 trial evaluating PLX-PAD in 240 patients for muscle recovery following hip fracture ...more  
Post by lucaM1on Jul 13, 2022 8:35am

Pluristem's CEO on today's results

 “While we were disappointed that this significant benefit did not translate to an SPPB score improvement, Pluristem will seek further regulatory advice to find a way to bridge the gap between ...more  
Post by lucaM1on Jul 10, 2022 9:55am

A New Food Ecosystem Emerges in Israel

The story of of Pluristem got into cultured meat.
Post by lucaM1on Jul 06, 2022 4:06am

Effective Cell Therapy for Cocaine Addiction

Pluristem's Placenta-Derived Mesenchymal-like Adherent Stromal Cells as an Effective Cell Therapy for Cocaine Addiction in a Rat Model ...more  
Post by lucaM1on Jul 04, 2022 8:45am

PSTI reminder.

A friendly reminder: If the phase 3 results of the muscle regeneration trials will be positive, the next step would be FDA approval!
Post by lucaM1on Jun 30, 2022 8:57am

$PSTI Q3 Wishlist

1.  Results from the multinational Phase III study for muscle regeneration following hip fracture surgery  2. Cultured meat proof of concept. 
Post by lucaM1on Jun 13, 2022 8:43am

Cultured meat proof of concept

Cultured meat proof of concept is right around the corner as the company said it will be published in Q2 at their investor call earlier this year. 
Post by lucaM1on Jun 07, 2022 9:31am

New PSTI Company blog.

How can Pluristem’s technology help the environment?
Post by lucaM1on May 25, 2022 10:22am

Bull run alert!

Bull run alert!  Watch out, $PSTI is already up by 6% to start the day!
Post by lucaM1on May 23, 2022 12:10pm

$PSTI vs S&P 500 YTD

$PSTI: -1% S&P 500: -17% $PSTI currently outperforming by 16%